CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The microbiota in radiotherapy-induced cancer immunosurveillance.
The microbiota in radiotherapy-induced cancer immunosurveillance.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
放疗在多种癌症患者的临床治疗中已确立其地位,因其能够优先杀伤恶性细胞,同时大多保护非恶性细胞。I-II期试验结果还提示,放疗可产生具有治疗相关性的免疫刺激效应,尤其是在与免疫检查点抑制剂联合应用时。过去二十年中,已有证据表明,肠道微生物群落对癌症患者的免疫张力具有重大影响,并可影响对多种免疫治疗的敏感性,包括免疫检查点抑制剂和CAR-T 细胞。在此,我们批判性地讨论此类微生物生态系统对放疗诱导的毒性和靶向肿瘤的免疫应答的影响,重点关注这些关系在预测性和治疗性临床应用中的临床潜力。
Radiotherapy has an established role in the clinical treatment of patients with a variety of cancers owing to the ability to preferentially kill malignant cells mostly while sparing their non-malignant counterparts. Results from phase I-II trials also suggest that radiotherapy can have therapeutically relevant immunostimulatory effects, especially when combined with immune-checkpoint inhibitors.
Over the past two decades, evidence has emerged showing that intestinal microbial communities have a major influence on the immunological tonus of patients with cancer and can influence sensitivity to various immunotherapies, including immune-checkpoint inhibitors and chimeric antigen receptor T cells.
Here, we critically discuss the effects of such microbial ecosystems on radiotherapy-induced toxicities and tumour-targeting immune responses, with a focus on the clinical potential of these relationships for predictive and therapeutic clinical applications.
MEMBER ACCOUNT
登录成功会直接打开下一页。